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Abstract
Background: Toxigenic Clostridium difficile is one of the prevalent diarrheagenic pathogens in hospitalized patients.
Objectives: The study assessed the ability of three diagnostic methods in identifying C. difficile strains. The genotyping of the isolates
was done, as well.
Methods: Stool samples were subjected to three different diagnostic methods including direct stool culture, glutamate dehydroge-
nase enzyme immunoassay (GDH-EIA), and direct stool PCR for the detection of the tcdA and tcdB genes. The sensitivity and specificity
of the tests were evaluated. The genotyping was done by the PFGE method.
Results: Of 120 samples, 20 (16%) were positive for C. difficile based on PCR, while 15 (12.5%) and 12 (10%) were positive according to
GDH-EIA and direct stool culture. Among patients with C. difficile-associated diseases (CDAD), 11 (61%) were more than 65-years-old.
The specificity of PCR, GDH-EIA, and direct culture was almost similar and equal to 100%, but their sensitivity was 90%, 70%, and 60%,
respectively. The positive predictive value (PPV) was lower for GDH-EIA than for the other two methods, and the highest negative
predictive value (NPV) was related to the PCR method. The results showed a high similarity between the isolates, and only were
three pulsotypes differentiated among the isolates.
Conclusions: The specificity and sensitivity of the direct stool PCR method were higher than those of the other two methods. Al-
though PCR inhibitors may reduce its ability for the correct diagnosis of negative samples, it seems to be a reliable method for the
detection of C. difficile infection. The weakness of the GDH-EIA method was its lower PPV, which can cause false-positive results. Toxin
patterns and pulsotypes of C. difficile isolates revealed a high similarity between the strains isolated from the same units.
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1. Background
Toxigenic Clostridium difficile is one of the primary di-
arrheagenic pathogens in hospitalized patients. Although
C. difficile can cause pseudomembranous colitis (PMC),
it is found in the normal fecal flora of 5% of healthy
adults (1). Other infections like antibiotic-associated col-
itis, antibiotic-associated diarrhea, and non-antibiotic-
associated diarrhea (2, 3) showed to be associated with C.
difficile. This bacterium is on the top list of agents caus-
ing healthcare-associated infections (HIAs). The intensity
of C. difficile infection (CDI) ranges from mild diarrhea to
PMC, which is caused by toxigenic strains and can lead to
death (4). The CDI has different risk factors, including hos-
pitalization, old age, and exposure to antibiotics such asβ-
lactams, clindamycin, and cephalosporins (5).
Healthcare-associated infections are considered a no-
ticeable threat to public health not only in developing
countries but also in developed ones such as the United
States and Europe (6). The pulsotype (NAP1)/ribotype 027
of C. difficile emerged in North America in 2003, and it has
been detected as a cause of CDI prevalence in the United
States and Canada (7-9). Since then, CDI has shown an
upward trend among hospitalized patients in a way that
roughly half a million cases and 29,000 deaths were re-
ported in 2012. Two-thirds of these cases were associated
with hospitalized patients, and the healthcare incidence
was 92.8 per 100,000 persons (10). In addition to the North
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American countries facing this public health threat, the
European countries are involved as well, as ribotype 078
was responsible for CDI prevalence in Europe in 2005 (11).
The incidence rate of CDI in Europe has been reported with
high variations. In a survey conducted in all European
countries in 2008, the average incidence rate of C. difficile
was reported as 4.1 per 100,000 patient-days per hospital,
in the range of 0.0 to 36.3 (12). Although the threat of CDI
among hospitalized patients is rapidly increasing world-
wide, the accurate estimation of this lethal infection in de-
veloping countries is still vague due to the lack of precise
and exact diagnostic and surveillance protocols.
The differential diagnosis of diarrhea in hospitalized
patients is important for choosing the treatment; for in-
stance, C. difficile is more likely to be the cause of infec-
tion than other enteric pathogens in patients with diar-
rhea arising after 72 h of hospitalization (13). In this or-
ganism, there are different virulence factors responsible
for C. difficile-associated diarrhea (CDAD) such as entero-
toxins, ADP-ribosylating toxin, and spore formation abil-
ity (14). Recent research determined that two exotoxins
of toxin A and toxin B (cytotoxin) are mainly associated
with primary colonic mucosal injury and inflammation
(15). Toxin A is an enterotoxin that can cause fluid secre-
tion and consequently, diarrhea and also act as a chemotac-
tic agent for neutrophils and cytokines secretion. Toxin B
has a strong cytotoxicity ability that can be lethal for many
cell lines (16). Many studies revealed that almost all clin-
ical isolates produced one or both toxins. It is evidenced
that rapid, accurate diagnosis of C. difficile is a critical key
in the CDI control and prevention. In recent studies, differ-
ent diagnostic methods have been developed for the detec-
tion of C. difficile isolates in clinical samples such as direct
culture, immunoassay, molecular detection, and cell cul-
ture. The key to the diagnosis of these bacteria is the power
of the selected method to differentiate toxigenic strains
from non-toxigenic strains. Although the cell cytotoxicity
assay (cell culture) is the “gold standard” method for the
identification of toxigenic strains, it is not time- and cost-
effective for the Healthcare System and Medical Laboratory
Section (17, 18). Another approach to the detection of C. dif-
ficile strains in clinical samples is the use of immunoassay
methods, including enzyme-linked immunosorbent assay
(19), which is used to detect toxins and other enzymes pro-
duced in the strains. For source tracking of CDI, the clinical
strains should be analyzed by molecular typing methods.
The PFGE is the standard gold method for strain genotyp-
ing, which can determine the genetic relationship among
strains with a high confidence level (20).
2. Objectives
In the present study, we determined the prevalence of
C. difficile strains among hospitalized patients at a teach-
ing hospital of Iran University of Medical Sciences, Tehran,
Iran, by using the PCR method to specify the toxigenic pat-
tern. Besides, three different methods were evaluated to se-
lect the most reliable one for the identification of C. difficile
isolates. Finally, the genetic relationship among C. difficile
strains isolated from stool samples of patients was deter-
mined by the PFGE technique.
3. Methods
3.1. Sample Collection
In this study, 120 stool samples were collected from
hospitalized patients at a teaching hospital of Iran Univer-
sity of Medical Sciences, Tehran, Iran, from February 2016
to January 2017. The inclusion criteria were defined as hav-
ing diarrhea symptoms, mid-term term or long-term hos-
pitalization (three days or more), taking antibiotics dur-
ing hospitalization, or having operations (21). The diarrhea
was diagnosed by a watery, loose, bloody, or mucoid stool
with at least three times a day frequency. The patients were
divided into three groups, including children and adoles-
cents (1-19-years-old), young and middle-aged individuals
(20-64-years-old), and the elderly (more than 65-years-old).
All stool samples were transferred to the Antimicrobial
Resistance Research Center and stored under the condi-
tions of the cold chain (4°C) for 4 h after sampling. The
samples were subjected to three different diagnostic meth-
ods, including (1) direct stool culture; (2) Glutamate dehy-
drogenase enzyme immunoassay (GDH-EIA) for C. difficile
using Clostridium K -SeT commercial kit (Coris BioConcept,
Belgium); and (3) direct stool PCR for the detection of tcdA
and tcdB genes.
3.2. Stool Culture and Bacterial Isolation
The isolation of C. difficile strains was conducted fol-
lowing the alcohol shock protocol (22). According to pre-
vious studies, 1 mL (or 1 g) of stool specimen was treated
with 1 mL absolute ethanol and incubated at room tem-
perature for 2 min, followed by culturing on cycloserine
cefoxitin fructose agar (CCFA) and pre-poured chromID
agar (Biomerieux SA, France) (23). The CCFA culture media
were supplemented with 7% defibrinated horse blood, 0.1%
sodium taurocholate, 250 µg.mL-1 cycloserine, 10 µg.mL-1
cefoxitin, and 250 µg.mL-1 amphotericin B to enhance the
germination of C. difficile spores and prevent the growth of
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other bacteria and fungi. Another 1 mL (or 1 g) of stool spec-
imen was mixed with 1 mL of 5% yeast extract and then im-
mediately cultured on the CCFA media to prevent the miss-
ing of C. difficile strains. All cultured media were incubated
in anaerobic conditions using a jar with a gas pack (Anae-
rocult A, Merck, Germany) at 37°C. Plates were monitored
for five days and the incubation of negative cultures con-
tinued for seven days. Then, C. difficile colonies having an
irregular edge and the odor of horse manure with Gram-
positive reactions were identified as large colonies. The
gray to black colonies after 24 h on Chrom ID were iden-
tified as positive colonies. Conventional biochemical tests
were performed to confirm the isolated strains from the
specific media. To finalize the diagnosis, motile strains that
were positive for producing gelatinase and H2S and neg-
ative for catalase, oxidase, and indole were confirmed as
Clostridium difficile.
3.3. Glutamate Dehydrogenase Enzyme Immunoassay for C. dif-
ficile
Glutamate dehydrogenase is a metabolic enzyme that
has recently shown to play a critical role in the rapid di-
agnosis of C. difficile, as all strains produce a high amount
of this enzyme. Clostridium K -SeT (Coris BioConcept, Bel-
gium) was used to direct detection of C. difficile strains
from stool samples. The cassettes were made of a nitrocel-
lulose membrane coated with an antibody (GDH) directed
against C. difficile antigen. The dilution buffer containing
Tris, EDTA, and NaN3 (< 0.1%) worked as a detergent and
protein blocker. All stool samples were tested with Clostrid-
ium K -SeT according to the manufacturer’s instruction. The
samples were recorded as positive when a reddish-purple
line appeared across the control (C) and test (T) lines on the
cassettes.
3.4. Direct PCR Amplification of Toxin Genes Sequences
Total DNA was extracted from fecal samples using QI-
Aamp DNA Stool Minikit (Qiagen, Germany) and used as
the DNA template in PCR. Two separate PCRs were carried
out using specific primers for the tcdA and tcdB genes (Ta-
ble 1). The PCR mixture consisted of a final volume of 25
µL containing 12.5 µL ready-to-use master mix (including
MgCl2, dNTP, and Taq enzyme) (SinaClon BioScience Co.
Iran), 0.25 µL of 10 nmol.µL-1 of each primer, 5 µL of ex-
tracted DNA, and sterile nuclease-free water. The PCR pro-
gram started by an initial denaturation at 93°C for 5 min,
followed by 30 cycles including denaturation at 95°C for
one minute, annealing at 52°C for one minute, extension
at 72°C for one minute, and a final extension at 72°C for 5
min; finally, the reaction was held at 4°C. The PCR prod-
ucts were separated by electrophoresis on a 1.5% agarose
gel and visualized with commercial DNA safe stain (Sina-
Clon BioScience Co. Iran). The images were captured us-
ing the UVItec gel documentation system (Cleaver Scien-
tific Ltd., United Kingdom)
Table 1. Primers Used in This Study















3.5. Evaluation of Diagnostic Methods Efficiency
The efficiency of diagnostic methods was evaluated by
interpreting the test results. In this survey, if the results of
two out of three different methods were positive, the sam-
ple would be considered a true positive. Also, four different
indices, including specificity, sensitivity, positive predic-
tive value (PPV), and negative predictive value (NPV) were
calculated for PCR, direct culture (DC), and GDH-EIA assay.
The PPV is the probability that a positive test result is truly
positive and the NPV is the probability that a negative test
result is truly negative. They were calculated as follows:
PPV = [true positive/true positive + false positive] × 100,
NPV = [true negative/true negative + false negative] × 100,
sensitivity = [true positive/true positive + false negative] ×
100, and specificity = [true negative/true negative + false
negative] × 100 (26).
3.6. PFGE Analysis of the Isolates
The genotyping of isolates was done according to the
PulseNetprotocol for C. botulinum with some modification
specified for C. difficile strains. Briefly, all isolates were cul-
tured on CCFA supplemented with blood, antibiotics, and
sodium taurocholate and incubated anaerobically for 48
h. Bacterial suspensions were made with 1 McFarland tur-
bidity. Cells were washed twice with 1,000 µL cell suspen-
sion buffer. The washed cells were inoculated on Egg Yolk
agar under anaerobic conditions. The grown colonies were
suspended in 1.5 mL of lysis buffer (12 mM Tris, 2 M NaCl,
200 mM EDTA, 1% Brij 58, 0.4% deoxycholate, and 1% Sar-
cosyl) until OD600 reached 0.8 - 1. The bacterial suspen-
sion was centrifuged, the supernatant was removed, and
the pellet was re-suspended in 400 µL of lysis buffer, pro-
teinase K (0.665 mg.mL-1), lysozyme (4 mg.mL-1), and 20U
mutanolysin and incubated in 55°C water bath for 20 - 30
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min. Melted 1.2% SeaKem Gold agarose (400µL) was added
to cell suspensions and mixed gently. The mixture was im-
mediately poured into the PFGE mold. Plugs were washed
using sterile ES buffer (10 mM Tris-HCl [pH = 7.5], 10 mM
Na2EDTA, plus proteinase K [0.14 mg.mL
-1]), incubated in
55°C shaker water bath for at least 2 h, and preheated in
55°C ultrapure sterile water two times; each time of shak-
ing was in the water bath at 55°C for 15 min. In the next step,
the plugs were washed six times with preheated (55°C) ster-
ile TE buffer. Each plug was cut into four pieces, each of
which was digested in one PFGE run. The sample plugs
were digested with 30 U SmaI restriction enzyme and 1 µg
of RNaseA and incubated at 25°C for at least one hour. Then,
the standard plugs (Salmonella ser. Braenderup H9812) were
digested with XbaI and incubated at 37°C to use as a DNA
size marker. The digested DNA fragments were separated
in 1.5% agarose in 0.5X TBE buffer with 200 µM thiourea
and electrophoresed for 22 h at 14°C with an initial switch
time of one second, final switch time of 35 s, and the gra-
dient of 6 V.cm-1. The isolates were classified in the same
pulsotype if they showed more than 80% similarity in their
patterns (27).
3.7. Statistical Analysis
The statistical analysis was done with SPSS version 21
software. The BioNumerics software (Applied Maths, Sint-
Martens-Latem, Belgium) was used to analyze the PFGE
patterns. The patterns were compared using the Dice co-
efficient and unweighted pair group method with arith-
metic averages (UPGMA) clustering. A dendrogram was
constructed using an optimization value of 0.5% and a po-
sition tolerance of 1.0%.
4. Results
During 12 months, 120 stool samples were collected
from patients in this study. All patients had a history of
surgical operation, infectious diseases, or antibiotic ther-
apy. A total of 18 (15%) out of 120 samples were positive for
the presence of C. difficile strains according to the molec-
ular diagnosis results, while 15 (12.5%) and 12 (10%) cases
were positive according to the GDH-EIA and direct stool
culture, respectively. Eight (16.3%) out of 49 women and
10 (14.1%) out of 71 men were identified as CDAD-positive.
Among patients with CDAD infection, 11 (61%) cases had
more than 65-years-old, which was significantly different
from the other two age groups (P < 0.05) (Table 2). All pos-
itive patients (except for one case) had been treated with
at least two or more types of antibiotics, especially fluoro-
quinolones and β-lactams. The exceptional case was hos-
pitalized in the Medical Intensive Care Unit (MICU) with
the diagnosis of chronic obstructive pulmonary disease
(COPD) that had taken only ceftriaxone before sampling.
Also, 12 (60%) out of 20 cases had received ciprofloxacin,
five (25%) cases metronidazole, six (30%) cases vancomycin,
and eight (40%) cases β-lactams including cephalosporins
and carbapenems.
Table 2. Frequency of Positive Samples for Clostridium difficile in Different Age
Groups and Gendersa
Gender 1 - 19 Years 20 - 64 Years > 65 Years
Female 2 (11.1) 1 (5.5) 5 (27.7)
Male 3 (16.6) 1 (5.5) 6 (33.4)
Total 5 (27.7) 2 (11.1) 11 (61.2)
aValues are expressed as No. (%).
4.1. Diagnosis of CDAD with PCR
The whole genome was analyzed in stool samples for
toxin detection using tcdA and tcdB specific primers. Ac-
cording to the results of PCR amplification, 251 and 418 bp
DNA bands (Figure 1) related to the tcdA and tcdB genes
were present in 17 (94%) and 16 (89%) isolates, respectively
(Table 3).
Table 3. Toxin Patterns of Clostridium difficile Isolated From Diarrheal Patientsa
Toxin Gene Pattern Values
tcdA+ , tcdB+ 15 (83.5)
tcdA+ , tcdB- 2 (11)
tcdA- , tcdB+ 1 (5.5)
Total 18 (100)
aValues are expressed as No. (%).
4.2. Efficiency of Diagnostic Methods
The sensitivity (the ability of a test to classify correctly
a sample as positive), specificity (the ability of a test to clas-
sify a sample correctly as negative), NPV, and PPV indices of
direct culture, GDH-EIA, and PCR assay are shown in Table
4. The PCR and direct culture methods had the highest ac-
curacy to detect the negative samples. The main problem
was the detection of true positive samples, as the sensitiv-
ity of direct culture and EIA-DGH assay was 60% and 70%,
respectively (Table 4).
4.3. Genotyping of the Isolates
Among 18 positive samples, only 12 C. difficile strains
were isolated via direct culture, and they all were subjected
to the PFGE assay. The fingerprints with 8 to 11 bands were
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Figure 1. PCR amplification of tcdA and tcdB genes among patients with CDAD. A, Amplification of tcdA; M: 1 kb DNA size marker; lane 1, confirmed C. difficile clinical isolate
used as a positive control; lane 2, E. coli ATCC 2599 as a negative control; lanes 3, 7, and 8, negative samples; lanes 4 - 6, positive samples for tcdA; B, amplification of tcdB; M: 1 kb
DNA size marker; lane 1, E. coli ATCC 2599 as a negative control; lane 2, confirmed C. difficile clinical isolate used as a positive control; lanes 3 - 8, positive samples.
Table 4. The Efficiency of Direct Culture and GDH-EIA Method in the Diagnosis of Clostridium difficile
Assay Number of Positive Samples Number of Negative Samples Specificity, % Sensitivity, % PPV NPV
PCR 18 102 100 90 100 98
Direct culture 12 108 100 60 100 92
GDH-EIA 15 105 99 70 93 94
detected in each isolate. The results showed a high simi-
larity between the isolates and only were three pulsotypes
(named as PF-A, PF-B, and PF-C) differentiated from the iso-
lates (Figure 2). The PF-A pulsotype was the most com-
mon pulsotype, determined in nine (75%) isolates, all of
which were isolated from hospitalized patients in the in-
ternal ward. The PF-B pulsotype was related to two pa-
tients who were admitted to the neurological ward. The
PF-Cpulsotype was determined in only one patient hospi-
talized in the MICU. As shown in Figure 2, a correlation was
detected between the pulsotypes and toxinotypes.
5. Discussion
As known, C. difficile is part of the normal intestinal
flora. It is considered an opportunistic pathogen during
the usage of antibiotics or surgical operations (28). Tox-
igenic strains of C. difficile can cause fatal infection and
nowadays, are the main nosocomial pathogens. According
to the studies, CDI is the cause of 10% - 20% of all antibiotic-
associated diarrhea cases and all colitis cases, occurring as
the consequences of antibiotic therapy worldwide (29). De-
termining the accurate prevalence rate and genetic pro-
files and using a quick, reliable method to identify C. diffi-
cile strains play a critical role in controlling and preventing
CDI in hospitals and healthcare settings.
According to previous studies conducted in Europe,
America, and some Asian countries, the prevalence and epi-
demiological profile of C. difficile are changing, and they
are completely different based on geographical disparities,
the type of therapies used by clinicians, and the different
genetic properties of C. difficile isolates (1, 10, 30). This has
been reported as a major risk for nosocomial infection con-
trol in a few studies conducted to determine the regional
prevalence and genotype patterns of C. difficile strains in
Iranian hospitals as hospital acquired Clostridium difficile
infection (HA-CDI) (31, 32). In the present study, the preva-
lence rate of HA-CDI was 15% among hospitalized patients,
which is almost consistent with the findings of other stud-
ies by Goudarzi et al. (31) and Jalali et al. (33), in which the
prevalence rate was reported as 21% and 20%, respectively.
In the current study, an upward trend was observed in
the prevalence of C. difficile among hospitalized patients in
Iran, as the prevalence of C. difficile reported by Sadeghifard
et al. (17) in 2005 was about 10.3%, only 6.1% of which were
toxigenic strains. This upward trend has been reported in
other studies conducted in Europe and the United States
(30, 34), in which not only the incidence of CDI among hos-
pitalized patients but also the community-acquired CDI
(CA-CDI) has been reported to be raising (35).
Based on other reports, CDI disproportionately affects
elderly patients (36). The results of this study asserted the
hypothesis of old age being as a risk factor for CDI, as 61%
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Figure 2. Dendrogram of genetic relationships among Clostridium difficile isolates and associated toxin patterns
of patients with positive PCR tests for C. difficile were more
than 65-years-old. However, contrary results were observed
in some studies. In a study conducted by Jalali et al. (33),
less than 30% of CDI patients were over 65-years-old, and
most of the positive patients were younger than 43 years.
Different diagnostic methods have been modified to the
approach of rapid and accurate diagnosis of CDI (16, 37,
38). According to the present study results, the direct stool
PCR toxin assay showed the highest sensitivity and speci-
ficity among other methods. The commercial Clostridium
K -SeT (Coris BioConcept, Belgium) produced based on the
EIA-GDH assay showed the potential of this method to use
as a reliable and rapid alternative for direct culture. The
sensitivity of this method was higher than that of direct
stool culture, indicating that this method can detect posi-
tive samples more accurately than direct culture does. The
specificity of both methods was almost 100%, indicating
that both have a great ability to recognize negative sam-
ples, but direct culture wrongly detects positive samples as
negative ones. This disparity occurs because of the external
errors during direct culture, including technician, mate-
rial, or instrument errors. Clostridium K -SeT can be used for
the rapid detection of C. difficile strains from stool samples
but the PCR toxin assay should be done for the final confir-
mation of toxigenic strains. The sensitivity of the PCR tech-
nique in detecting low amounts of bacterial DNA in sam-
ples and reducing external errors relative to other meth-
ods introduces PCR as a reliable method for the diagnosis
of bacterial strains, especially in the case of toxigenic C. dif-
ficile strains.
The PFGE method was performed for C. difficile isolates
genotyping. Different typing methods have been used
for C. difficile genotyping (39, 40) but PFGE has been in-
troduced as a Gold standard (41). Three different pulso-
types (PF-A, PF-B, and PF-C) were recognized among the iso-
lates, each of which was related to a different toxin pat-
tern, indicating the effectiveness of PFGE in recognizing ge-
netics contents (Figure 2). The PF-A pulsotype associated
with strains isolated from internal ward patients had the
tcdA+/tcdB+ toxin pattern and it was the most common pul-
sotype (75%). The PF-B pulsotype associated with strains iso-
lated from neurological ward patients had the tcdA+/tcdB-
toxin profile. The PF-C pulsotype associated with one strain
isolated from a patient with COPD hospitalized in the MICU
showed the tcdA-/tcdB+ toxin pattern. Some studies showed
that COPD could encounter CDI, but some others claimed
that CDI could increase in COPD patients because of early
antibiotic administration. The internal and neurological
wards were located in different parts of the hospital and it
could be the reason for patients to be infected with differ-
ent colons of C. difficile. It is worth noting that patients in
the same ward had HA-CDI caused by the clonally related
isolates. The transmission of CDI among patients is a crit-
ical threat in nosocomial infection control, which should
be prevented by using high-level hygiene protocols.
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5.1. Conclusions
The PCR toxin assay is a reliable method for the accu-
rate diagnosis of CDI. Although the EIA-GDH assay has a
lower sensitivity, it can be used for rapid screening and the
results should be confirmed by molecular methods. In ad-
dition, the toxin patterns and genotypes of C. difficile iso-
lates were compatible with each other and provided essen-
tial data for source tracking and controlling CDI distribu-
tion.
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